Cargando…

Multiple anti-tumor effects of Reparixin on thyroid cancer

BACKGROUND: Expression of IL-8 and its receptors CXCR1 and CXCR2 is a common occurrence in human epithelial thyroid cancer (TC). In human TC samples, IL-8 expression is associated with tumor progression. IL-8 enhances proliferation, survival, motility, and leads to the maintenance of stemness featur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liotti, Federica, De Pizzol, Maria, Allegretti, Marcello, Prevete, Nella, Melillo, Rosa Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482629/ https://www.ncbi.nlm.nih.gov/pubmed/28415590 http://dx.doi.org/10.18632/oncotarget.16412

Ejemplares similares

The Impact of Resolution of Inflammation on Tumor Microenvironment: Exploring New Ways to Control Cancer Progression
por: Liotti, Federica, et al.
Publicado: (2022)

Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies
por: Liotti, Federica, et al.
Publicado: (2019)

Tumor-Associated Mast Cells in Thyroid Cancer
por: Visciano, Carla, et al.
Publicado: (2015)

Toll-Like Receptor 7 Mediates Inflammation Resolution and Inhibition of Angiogenesis in Non-Small Cell Lung Cancer
por: Liotti, Federica, et al.
Publicado: (2021)

PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells
por: Liotti, Federica, et al.
Publicado: (2021)

The lncRNA RMST is drastically downregulated in anaplastic thyroid carcinomas where exerts a tumor suppressor activity impairing epithelial-mesenchymal transition and stemness
por: De Martino, Marco, et al.
Publicado: (2023)

A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
por: Landoni, Giovanni, et al.
Publicado: (2022)

Probiotic Lactobacillus rhamnosus GG (LGG) restrains the angiogenic potential of colorectal carcinoma cells by activating a proresolving program via formyl peptide receptor 1
por: Liotti, Federica, et al.
Publicado: (2022)

The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1 (low) Mice
por: Verachi, Paola, et al.
Publicado: (2022)

AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer
por: Collina, Francesca, et al.
Publicado: (2019)

Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study
por: Piemonti, Lorenzo, et al.
Publicado: (2023)

Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer
por: Malfitano, Anna Maria, et al.
Publicado: (2019)

The protective effects of reparixin against endothelial ischemia-reperfusion injury
por: Thitiwuthikiat, Piyanuch, et al.
Publicado: (2022)

Glucose Enhances Pro-Tumorigenic Functions of Mammary Adipose-Derived Mesenchymal Stromal/Stem Cells on Breast Cancer Cell Lines
por: Ambrosio, Maria Rosaria, et al.
Publicado: (2022)

Reply to Comment on “Malfitano, A.M. et al. Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer” Cancers 2019, 11, 1532
por: Malfitano, Anna Maria, et al.
Publicado: (2020)

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies
por: Ieranò, Caterina, et al.
Publicado: (2022)

The effect of reparixin on survival in patients at high risk for in-hospital mortality: a meta-analysis of randomized trials
por: Landoni, Giovanni, et al.
Publicado: (2022)

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
por: Goldstein, Lori J., et al.
Publicado: (2020)

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer
por: Goldstein, Lori J., et al.
Publicado: (2020)

Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice: Ischemia and Reparixin
por: da Cunha Sousa, Larissa Fonseca, et al.
Publicado: (2013)

Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment
por: Kemp, Daria Marley, et al.
Publicado: (2017)

Interleukin-8 as a therapeutic target for chronic low back pain: Upregulation in human cerebrospinal fluid and pre-clinical validation with chronic reparixin in the SPARC-null mouse model
por: Krock, Emerson, et al.
Publicado: (2019)

Letter to the Editor Regarding a Multicentric Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
por: Ito, Shun, et al.
Publicado: (2022)

Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling
por: Brandolini, Laura, et al.
Publicado: (2015)

Response to “Letter to the Editor Regarding a Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia”
por: Mantelli, Flavio
Publicado: (2022)

Differential diagnosis of thyroid nodules using fine-needle aspiration cytology and oncogene mutation screening: are we ready?
por: Melillo, Rosa Marina, et al.
Publicado: (2010)

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
por: Goldstein, Lori J., et al.
Publicado: (2021)

The N-Formyl Peptide Receptors and Rheumatoid Arthritis: A Dangerous Liaison or Confusing Relationship?
por: Mormile, Ilaria, et al.
Publicado: (2021)

Parathyroid Hormone Causes Endothelial Dysfunction by Inducing Mitochondrial ROS and Specific Oxidative Signal Transduction Modifications
por: Gambardella, Jessica, et al.
Publicado: (2018)

AXL is an oncotarget in human colorectal cancer
por: Martinelli, Erika, et al.
Publicado: (2015)

Stromal and Immune Cell Dynamics in Tumor Associated Tertiary Lymphoid Structures and Anti-Tumor Immune Responses
por: Rossi, Alessandra, et al.
Publicado: (2022)

Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells
por: Ambrosio, Maria Rosaria, et al.
Publicado: (2017)

The Urokinase/Urokinase Receptor System in Mast Cells: Effects of its Functional Interaction with fMLF Receptors
por: Rossi, Francesca Wanda, et al.
Publicado: (2016)

HIV-1 Nef promotes migration and chemokine synthesis of human basophils and mast cells through the interaction with CXCR4
por: Rossi, Francesca Wanda, et al.
Publicado: (2016)

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer
por: Brauner, Eran, et al.
Publicado: (2016)

Editorial: Further advances in understanding the endocrine cancer microenvironment
por: Coperchini, Francesca, et al.
Publicado: (2022)

The Role of Endogenous Eicosapentaenoic Acid and Docosahexaenoic Acid-Derived Resolvins in Systemic Sclerosis
por: Avanoǧlu Güler, Aslıhan, et al.
Publicado: (2020)

The anti-cancer effects of phenformin in thyroid cancer cell lines and in normal thyrocytes
por: Coperchini, Francesca, et al.
Publicado: (2019)

Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2017)

GRK2 moderates the acute mitochondrial damage to ionizing radiation exposure by promoting mitochondrial fission/fusion
por: Franco, Antonietta, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7ag8012b4npkmflfcg3d3p7k5o